Biogen
NEWS
Novartis filed a federal lawsuit against a former executive, Alisha Alaimo. The lawsuit alleged that Alaimo stole confidential files using a flash drive before joining Biogen.
Yesterday’s news that Takeda Pharmaceuticals was considering acquiring Shire is raising the possibility of a bidding war. But it’s also having decidedly different effects on the two companies’ stock prices.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
Ionis Pharmaceuticals has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion.
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.
Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.
After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.
JOBS
IN THE PRESS